Singh Sarika, Rath Ashutosh, Yadav Surekha
Department of Pathology, Maulana Azad Medical College, New Delhi, India.
Sultan Qaboos Univ Med J. 2018 Aug;18(3):e397-e401. doi: 10.18295/squmj.2018.18.03.024. Epub 2018 Dec 19.
Plasma cell leukaemia (PCL) is one of the most aggressive and rarest forms of plasma cell dyscrasia. However, the diagnostic criteria for this condition have not yet been revised and there is no specific treatment to significantly improve the course of the disease. We report a 69-year-old male who presented to the Lok Nayak Hospital, New Delhi, India, in 2017 with dyspnoea and chest pain. A peripheral blood smear showed an absolute plasma cell count of 2.16 × 10/L. A bone marrow examination showed 61% atypical plasma cells exhibiting kappa light chain restriction. Biochemical investigations were consistent with a diagnosis of primary PCL with renal involvement. Bortezomib-based chemotherapy was initiated, which resulted in an improvement in the patient's haematological and biochemical parameters. This case report includes a comprehensive review of the clinical and diagnostic features, pathobiology and treatment of PCL.
浆细胞白血病(PCL)是浆细胞发育异常中最具侵袭性且最为罕见的形式之一。然而,该病的诊断标准尚未修订,也没有能显著改善病程的特异性治疗方法。我们报告一例69岁男性患者,2017年因呼吸困难和胸痛就诊于印度新德里的洛克·纳亚克医院。外周血涂片显示绝对浆细胞计数为2.16×10/L。骨髓检查显示61%的非典型浆细胞表现为κ轻链限制。生化检查结果符合原发性PCL伴肾脏受累的诊断。开始使用基于硼替佐米的化疗,患者的血液学和生化指标有所改善。本病例报告全面回顾了PCL的临床和诊断特征、病理生物学及治疗情况。